Travere Therapeutics Q3 Adj EPS $2.27 Up From $(0.86) YoY, Sales $37.09M Up From $28.07M YoY
Portfolio Pulse from totan@benzinga.com
Travere Therapeutics reported Q3 earnings of $2.27 per share, a 363.95% increase YoY, and sales of $37.09M, a 32.13% increase YoY.
November 07, 2023 | 9:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics reported a significant increase in Q3 earnings and sales YoY.
Travere Therapeutics reported a significant increase in Q3 earnings and sales compared to the same period last year. This positive financial performance could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100